

( (S (NP-SBJ-1 (NP Britain 's)
	       Monopolies and Mergers Commission)
     (NP-TMP Wednesday)
     (VP cleared
         (NP (NP (NP Rhone-Poulenc S.A. 's)
		 purchase)
             (PP of
                 (NP a specialty bulk-chemical unit))
             (PP from
                 (NP Monsanto Co.)))
	 ,
	 (S-ADV (NP-SBJ *-1)
		(VP saying
		    (SBAR 0
			  (S (NP-SBJ-2 the purchase)
			     (VP was
				 (ADJP-PRD unlikely
					   (S (NP-SBJ *-2)
					      (VP to
						  (VP have
						      (NP (NP any lasting impact)
							  (PP-LOC on
								  (NP U.K. industrial consumers)))))))))))))
     .))
( (S (NP-SBJ (NP The commission)
             ,
             (SBAR (WHNP-1 which)
                   (S (NP-SBJ-3 *T*-1)
                      (VP was
                          (VP asked
			      (NP-4 *-3)
                              (S (NP-SBJ *-4)
                                 (VP to
                                     (VP study
                                         (NP the deal))))
                              (PP-LGS by
				      (NP (NP the Department)
					  (PP of
					      (NP Trade and Industry))))
                              (PP-TMP after
				      (NP (NP its announcement)
					  (PP-TMP in
						  (NP February))))))))
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP the diversity)
                          (PP of
                              (NP (NP global supply)
                                  (PP of
                                      (NP (NP chemicals)
                                          (VP used
                                              (NP *)
                                              (PP-LOC-CLR in
							  (S-NOM (NP-SBJ *)
								 (VP making
								     (NP analgesic drugs))))))))))
                  (VP was
                      (ADJP-PRD great enough
                                (S (NP-SBJ *)
                                   (VP to
                                       (VP offset
                                           (NP (NP the dominant U.K. market share)
                                               (SBAR (WHNP-2 0)
                                                     (S (NP-SBJ Rhone-Poulenc)
                                                        (VP would
                                                            (VP gain
                                                                (NP *T*-2)
                                                                (PP through
                                                                    (NP the acquisition)))))))))))))))
     .))
( (S (NP-SBJ The French chemical giant)
     (VP would
         (VP hold
             (NP (NP an (ADJP 80 %) share)
                 (PP of
                     (NP (NP the U.K. market)
                         (PP for
                             (NP (NP salicylic acid)
                                 ,
                                 (NP methyl salicylate)
                                 and
                                 (NP bulk aspirin))))))))
     .))
( (S (NP-SBJ The commission)
     (VP found
         (SBAR that
               (S (SBAR-ADV if
			    (S (NP-SBJ-2 the British government)
			       (VP attempted
				   (S (NP-SBJ *-2)
				      (VP to
					  (VP block
					      (NP the merger)))))))
                  ,
                  (NP-SBJ-3 Rhone-Poulenc)
                  (VP would
                      (ADVP likely)
                      (VP respond
                          (PP-MNR by
				  (S-NOM (NP-SBJ *-3)
					 (VP closing
					     (NP (NP the salicylates plant)
						 (SBAR (WHNP-1 0)
						       (S (NP-SBJ Monsanto)
							  (VP operates
							      (NP *T*-1))))
						 (PP-LOC in
							 (NP Wales))))))
                          ,
                          (S-ADV (NP-SBJ *-3)
				 (VP removing
				     (NP the matter)
				     (PP-DIR from
					     (NP U.K. jurisdiction)))))))))
     .))
